DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1570 Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes
among patients with multidrug-resistant tuberculosis: systematic
review and meta-analysis. Lancet Infect Dis, 2009,
9:153–161.
Parsons LM, Salfinger M, Clobridge A, et al. Phenotypic and
molecular characterization of Mycobacterium tuberculosis isolates
resistant to both isoniazid and ethambutol. Antimicrob
Agents Chemother, 2005, 49:2218–2225.
Peloquin CA, Bulpitt AE, Jaresko GS, et al. Pharmacokinetics
of ethambutol under fasting conditions, with food, and with
antacids. Antimicrob Agents Chemother, 1999, 43:568–572.
Peloquin CA, Zhu M, Adam RD, et al. Pharmacokinetics of paraaminosalicylic
acid granules under four dosing conditions. Ann
Pharmacother, 2001, 35:1332–1338.
Prasad K, Singh MB. Corticosteroids for managing tuberculous
meningitis. Cochrane Database Syst Rev, 2008, CD002244.
Rad ME, Bifani P, Martin C, et al. Mutations in putative mutator
genes of Mycobacterium tuberculosis strains of the W-Beijing
family. Emerg Infect Dis, 2003, 9:838–845.
Roy PD, Majumder M, Roy B. Pharmacogenomics of anti-TB
drugs-related hepatotoxicity. Pharmacogenomics, 2008,
9:311–321.
Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity
and pharmacokinetics of the diarylquinoline TMC207 in
treatment of pulmonary tuberculosis. Antimicrob Agents
Chemother, 2008a, 52:2831–2835.
Rustomjee R, Lienhardt C, Kanyok T, et al. A Phase II study of
the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin
in pulmonary tuberculosis. Int J Tuberc Lung Dis,
2008b, 12:128–138.
Safi H, Sayers B, Hazbón MH, Alland D. Transfer of embB
codon 306 mutations into clinical Mycobacterium tuberculosis
strains alters susceptibility to ethambutol, isoniazid,
and rifampin. Antimicrob Agents Chemother, 2008, 52:
2027–2034.
Salfinger M, Heifets LB. Determination of pyrazinamide MICs
for Mycobacterium tuberculosis at different pHs by the radiometric
method. Antimicrob Agents Chemother, 1988,
32:1002–1004.
Simpson JA, Hughes D, Manyando C, et al. Population pharmacokinetic
and pharmacodynamic modeling of the antimalarial
chemotherapy chloproguanil/dapsone. Br j Clin Pharmacol,
2006, 61:289–300.
Singh R, Manjunatha U, Boshoff HI, et al. PA-824 kills nonreplicating
Mycobacterium tuberculosis by intracellular NO
release. Science, 2008, 322:1392–1395.
Somoskovi A, Parsons LM, Salfinger M. The molecular basis of
resistance to isoniazid, rifampin, and pyrazinamide in
Mycobacterium tuberculosis. Respir Res, 2001, 2:164–168.
Spies FS, da Silva PE, Ribeiro MO, et al. Identification of mutations
related to streptomycin resistance in clinical isolates of
Mycobacterium tuberculosis and possible involvement of
efflux mechanism. Antimicrob Agents Chemother, 2008,
52:2947–2949.
SECTION VII
CHEMOTHERAPY OF MICROBIAL DISEASES
Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule
nitroimidazopyran drug candidate for the treatment of tuberculosis.
Nature, 2000, 405:962–966.
Sullivan EA, Geoffroy P, Weisman R, et al. Isoniazid poisonings
in New York City. J Emerg Med, 1998, 16:57–59.
Tasneen R, Tyagi S, Williams K, et al. Enhanced bactericidal
activity of rifampin and/or pyrazinamide when combined with
PA-824 in a murine model of tuberculosis. Antimicrob Agents
Chemother, 2008, 52:3664–3668.
Timmins GS, Deretic V. Mechanisms of action of isoniazid. Mol
Microbiol, 2006, 62:1220–1227.
Vannelli TA, Dykman A, Ortiz de Montellano PR. The antituberculosis
drug ethionamide is activated by a flavoprotein
monooxygenase. J Biol Chem, 2002, 277:12824–12829.
Volmink J, Garner P. Directly observed therapy for treating
tuberculosis. Cochrane Database Syst Rev, 2007, CD003343.
Warner DF, Mizrahi V. Tuberculosis chemotherapy: The influence
of bacillary stress and damage response pathways on drug
efficacy. Clin Microbiol Rev, 2006, 19:558–570.
Weiner M, Burman W, Luo CC, et al. Effects of rifampin and multidrug
resistance gene polymorphism on concentrations of moxifloxacin.
Antimicrob Agents Chemother, 2007, 51:2861–2866.
Wilkins JJ, Langdon G, McIlleron H, et al. Variability in the population
pharmacokinetics of pyrazinamide in South African
tuberculosis patients. Eur J Clin Pharmacol, 2006, 62:727–735.
Wilkins JJ, Savic RM, Karlsson MO, et al. Population pharmacokinetics
of rifampin in pulmonary tuberculosis patients, including
a semimechanistic model to describe variable absorption.
Antimicrob Agents Chemother, 2008, 52:2138–2148.
Wolf R, Matz H, Orion E, Tuzun B, Tuzun Y. Dapsone. Dermatol
Online J, 2002, 8:2.
Zhang Y, Permar S, Sun Z. Conditions that may affect the results
of susceptibility testing of Mycobacterium tuberculosis to
pyrazinamide. J Med Microbiol, 2002, 51:42–49.
Zhang Y, Scorpio A, Nikaido H, Sun Z. Role of acid pH and deficient
efflux of pyrazinoic acid in unique susceptibility of
Mycobacterium tuberculosis to pyrazinamide. J Bacteriol,
1999, 181:2044–2049.
Zhang Y, Wade MM, Scorpio A, et al. Mode of action of pyrazinamide:
Disruption of Mycobacterium tuberculosis membrane
transport and energetics by pyrazinoic acid. J Antimicrob
Chemother, 2003, 52:790–795.
Zhu M, Burman WJ, Starke JR, et al. Pharmacokinetics of
ethambutol in children and adults with tuberculosis. Int J
Tuberc Lung Dis, 2004, 8:1360–1367.
Zhu M, Namdar R, Stambaugh JJ, et al. Population pharmacokinetics
of ethionamide in patients with tuberculosis.
Tuberculosis (Edinb), 2002, 82:91–96.
Zhu M, Nix DE, Adam RD, et al. Pharmacokinetics of cycloserine
under fasting conditions and with high-fat meal, orange
juice, and antacids. Pharmacotherapy, 2001, 21:891–897.
Zimhony O, Cox JS, Welch JT, et al. Pyrazinamide inhibits the
eukaryotic-like fatty acid synthetase I (FASI) of
Mycobacterium tuberculosis. Nat Med, 2000, 6:1043–1047.